Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3H-1000
- Development stage
- Preclinical
- Lead developer
- 3H (Shanghai) Pharmaceuticals
01
Overview
3H-1000 (also known as Project 1000) is a biologic drug candidate currently in the early discovery and preclinical stages of development by 3H (Shanghai) Pharmaceuticals. Categorized as a biological macromolecule, the asset is being investigated for the treatment of both cancer and autoimmune diseases. While 3H Pharmaceuticals focuses on the development of dual-targeted antibodies, antibody-drug conjugates (ADCs), and small molecules for immuno-oncology, the specific molecular target and mechanism of action for 3H-1000 have not been publicly disclosed. The company has identified the autoimmune indication for this project as a potential first-in-class (FIC) therapy.
Beyond the preview
Go deeper on 3H-1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3H-1000.